1. PI3K/Akt/mTOR
  2. PI3K

Duvelisib (Synonyms: IPI-145; INK1197)

Cat. No.: HY-17044 Purity: 99.65%
Data Sheet SDS Handling Instructions

Duvelisib is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.

For research use only. We do not sell to patients.
Duvelisib Chemical Structure

Duvelisib Chemical Structure

CAS No. : 1201438-56-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $88 In-stock
5 mg $80 In-stock
10 mg $110 In-stock
50 mg $210 In-stock
100 mg $260 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Duvelisib:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Duvelisib is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.

IC50 & Target

IC50: 1 nM (PI3K δ), 50 nM (PI3K γ)

In Vitro

PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells[1]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02598570 AbbVie|Infinity Pharmaceuticals, Inc. Lymphoma November 2015 Phase 1
NCT02711852 Verastem, Inc. Hematologic Malignancy April 2016 Phase 2
NCT02783625 Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University Lymphoma|Relapsed/Refractory T-cell Lymphomas May 2016 Phase 1
NCT02292225 Verastem, Inc. Lymphocytic Leukemia, Chronic|Lymphoma, Small Lymphocytic February 2015 Phase 1
NCT01882803 Verastem, Inc. Indolent Non-Hodgkin Lymphoma May 2013 Phase 2
NCT02576275 Verastem, Inc. Indolent Non-Hodgkin's Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma December 2015 Phase 3
NCT02307461 Verastem, Inc. Healthy November 2014 Phase 1
NCT02640833 AbbVie|Infinity Pharmaceuticals, Inc. Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Non-Hodgkin Lymphoma July 2016 Phase 1
NCT02204982 Verastem, Inc. Follicular Lymphoma September 2014 Phase 3
NCT02391545 Verastem, Inc. CD20+ Follicular Lymphoma December 2014 Phase 1|Phase 2
NCT02004522 Verastem, Inc. Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma November 2013 Phase 3
NCT02049515 Verastem, Inc. Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma December 2013 Phase 3
NCT01476657 Verastem, Inc. Hematologic Malignancies October 2011 Phase 1
NCT02605694 Verastem, Inc. Lymphoma December 2015 Phase 2
NCT02095587 Verastem, Inc. Hepatic Impairment March 2014 Phase 1
NCT01836861 Verastem, Inc. Healthy March 2013 Phase 1
NCT01549106 Verastem, Inc. Healthy Volunteers August 2011 Phase 1
NCT02028039 M.D. Anderson Cancer Center|Infinity Pharmaceuticals, Inc. Leukemia December 2013 Phase 2
NCT01947777 Verastem, Inc. Healthy October 2013 Phase 1
NCT02158091 Dana-Farber Cancer Institute|Verastem, Inc. Chronic Lymphocytic Leukemia July 2014 Phase 1|Phase 2
NCT01925911 Verastem, Inc. Healthy August 2013 Phase 1
NCT01871675 SCRI Development Innovations, LLC|Infinity Pharmaceuticals, Inc. Lymphoma|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|T-cell Lymphoma May 2013 Phase 1
NCT01653756 Verastem, Inc. Asthma July 2012 Phase 2
NCT01851707 Verastem, Inc. Rheumatoid Arthritis April 2013 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.3989 mL 11.9944 mL 23.9889 mL
5 mM 0.4798 mL 2.3989 mL 4.7978 mL
10 mM 0.2399 mL 1.1994 mL 2.3989 mL
Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 41 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.65%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: